Top

Clinical Rheumatology

Published in:

01-10-2010 | Letter to Editor

The role of IL-23/IL-17 axis in the etiopathogenesis of Behçet's disease

Authors: Rui-Xue Leng, Gui-Mei Chen, Hai-Feng Pan, Dong-Qing Ye

Published in: Clinical Rheumatology | Issue 10/2010

Excerpt

Dear Editor, …

Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG (2010) Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations. Clin Rheumatol. doi:10.1007/s10067-010-1491-6

Alayli G, Aydin F, Coban AY, Süllü Y, Cantürk F, Bek Y, Durupinar B, Cantürk T (2007) T helper 1 type cytokines polymorphisms: association with susceptibility to Behçet's disease. Clin Rheumatol 26:1299–1305CrossRefPubMed

Habibagahi Z, Habibagahi M, Heidari M (2010) Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet's disease. Mod Rheumatol 20:154–159CrossRefPubMed

Lew W, Chang JY, Jung JY, Bang D (2008) Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet's disease. Br J Dermatol 158:505–511CrossRefPubMed

Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, Huang X, Kijlstra A (2008) Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 49:3058–3064CrossRefPubMed

Jiang Z, Yang P, Hou S, Du L, Xie L, Zhou H, Kijlstra A (2010) IL-23R gene confers susceptibility to Behcet's disease in a Chinese Han population. Ann Rheum Dis. doi:10.1136/ard.2009.119420 PubMed

Jang WC, Nam YH, Ahn YC, Lee SH, Park SH, Choe JY, Lee SS, Kim SK (2008) Interleukin-17F gene polymorphisms in Korean patients with Behçet's disease. Rheumatol Int 29:173–178CrossRefPubMed

Title: The role of IL-23/IL-17 axis in the etiopathogenesis of Behçet's disease
Authors: Rui-Xue Leng
Gui-Mei Chen
Hai-Feng Pan
Dong-Qing Ye
Publication date: 01-10-2010
Publisher: Springer-Verlag
Published in: Clinical Rheumatology / Issue 10/2010
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-010-1531-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2010

Clinical observations on the significance of raised cardiac troponin-T in patients with myositis of varying etiologies seen in rheumatology practice

Soluble receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation

Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis—a pilot study

Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis

Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis

Does exercise affect the antioxidant system in patients with ankylosing spondylitis?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials